Immunomedics inks therapy joint venture

Article

Immunomedics of Morris Plains, NJ, announced this month that it has entered into a joint venture with Beckman Coulter. The venture, IBC Pharmaceuticals, will take advantage of the two companies' compatible technologies to develop new cancer treatments.

Immunomedics of Morris Plains, NJ, announced this month that it has entered into a joint venture with Beckman Coulter. The venture, IBC Pharmaceuticals, will take advantage of the two companies' compatible technologies to develop new cancer treatments.

Immunomedics will supply its technological and marketing expertise to the venture, as well as one of its antibody patents. Fullerton, CA-based Beckman Coulter will contribute a bispecific antibody targeting technology developed by the company's Immunotech subsidiary in Marseilles, France. The technology, called the affinity enhancement system, works in a two-pronged method: A patient is first injected with the bispecific antibody that attaches to cancer cells, then is injected with a therapeutic. The process allows the tumor-killing drug to bind directly to cancer cells and kill them selectively, without affecting healthy tissue.

Immunomedics will continue its own R&D program independently of IBC, according to company chairman Dr. David Goldenberg. In addition to other diagnostic agents, Immunomedics has therapeutic agent CEA-Cide in phase I/II dose-ranging trials.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.